Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS
Phase of Trial: Phase IV
Latest Information Update: 25 Nov 2015
At a glance
- Drugs Vildagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Jun 2015 Primary end point (glycemic variability indices) met as per the abstract published in 75th Annual Scientific Sessions of the American Diabetes Association.